By Michael Dabaie

 

Bristol Myers Squibb said the European Commission granted full marketing authorization for Onureg as a maintenance therapy in acute myeloid leukemia.

Bristol Myers said the authorization approves use of Onureg in all European Union member states, as well as Norway, Iceland and Liechtenstein.

In the pivotal QUAZAR AML-001 study, Onureg significantly improved overall survival and relapse-free survival in patients with acute myeloid leukemia, the company said.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

June 18, 2021 10:08 ET (14:08 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Jul 2021 to Aug 2021 Click Here for more Bristol Myers Squibb Charts.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2020 to Aug 2021 Click Here for more Bristol Myers Squibb Charts.